

## AuSCR Research Task Group approved projects

<b>Title</b>	Australian Stroke Clinical Registry – Return on Investment
<b>Principle investigator</b>	Dr Joosup Kim
<b>Institute</b>	Monash University
<b>Co-investigators</b>	Professor Dominique Cadilhac , Dr Tharshanah Thayabaranathan, Mr Kushal Saini. Other: AuSCR Management/ Steering Committee members to be invited to contribute to a working group for this project.
<b>Submission date</b>	9 <sup>th</sup> September 2023
<b>AuSCR role</b>	Data provision
<b>Approved</b>	12 April 2024
<b>Status</b>	In progress

### Summary

There is limited evidence of the costs and benefits of clinical quality registries. In a recent systematic review (Lee et al, 2019, BMJ Open), three peer-reviewed manuscripts of economic evaluations of clinical registries were identified. These were conducted in registries related to surgical outcomes and sepsis in the USA, Canada and Australia. In a report on the economic evaluation of clinical quality registries in Australia prepared by The Australian Commission on Safety and Quality in Health Care in 2016, it was estimated that clinical quality registries had a benefit-to-cost ratio of 1.6 to 5.5, and an internal rate of return of 23%-52%. In another recently published peer-reviewed manuscript, the costs and benefits of the Victorian Cardiac Outcomes Registry was reported. It was found that for every dollar spent, there was a return over \$4.30 over 5 years.

Since the inception of the AuSCR in 2009, there have been significant improvements to the quality of care observed. There is a gap in the literature related to the cost effectiveness or return-on-investment of clinical registries related to stroke. Having data on costs and benefits will provide evidence to policymakers to support funding for the AuSCR.

In this study, we aim to understand the impact of the AuSCR and the value it brings to stroke care in Australia.

### Research questions:

- What are the costs and benefits of quality improvement initiatives related to the AuSCR?
  - What are the operational costs of the AuSCR?
  - What is the cost effectiveness or return-on-investment from the AuSCR?
  - What is the minimum number of patients that need to be treated with a certain evidence-based therapy for the AuSCR to be considered cost effective or have a positive return on investment?
-